Compare Allbirds Inc (BIRD) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Allbirds Inc vs Novartis AG — how do they compare? Allbirds Inc trades at $2.6 (market cap $22.68M), while Novartis AG trades at $153.53 (market cap $298.18B). The key difference: Novartis AG is far larger — about 13147.3× Allbirds Inc's market cap, and Novartis AG pays a 3.02% dividend while Allbirds Inc pays none. Which is the better fit depends on your goals.
| BIRD | NVS | |
|---|---|---|
Market Cap | $22.68M | $298.18B |
Sector | Consumer Cyclical | Health |
52-Week High | $16.99 | $168.62 |
52-Week Low | $2.21 | $119.31 |
Enterprise Value | $41.54M | $339.50B |
Dividend Yield | — | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIRD (Smartbird) trades at $2.53, up 5.42% with a bullish technical signal despite mixed earnings. The company completed a strategic pivot from footwear to AI infrastructure in June 2026, appointing former AWS executive Nadia Carlsten as CEO. While revenue declined to $152M in 2025 with a -53.4% net margin, the P/S ratio of 0.15 suggests potential undervaluation relative to AI sector peers.
The outlook hinges on successful execution of the AI infrastructure strategy, though significant execution risks remain given negative cash flows and lack of profitability. Analyst consensus shows cautious optimism with 21% buy ratings amid high institutional hold positions. Near-term catalysts include new board appointments and AI business development progress.
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Allbirds Inc
Allbirds Inc is a global lifestyle brand that innovates with naturally derived materials to make footwear and apparel products. Its primary source of revenue is from sales of shoes and apparel products in its directly owned digital and physical retail channels.
Read more on BIRD →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
